Bayer Healthcare Pharmaceuticals Inc., a subsidiary of the global pharmaceutical company Bayer AG, has been awarded a $840 million multiple award Federal Supply Schedule (FSS-61-IB) contract by the U.S. Department of Veterans Affairs (VA) for the supply of a wide range of pharmaceutical and drug products. This contract allows various federal agencies to place delivery orders for needed medications and medical supplies. Bayer Healthcare Pharmaceuticals Inc. has also been awarded a $45 million Blanket Purchase Agreement (BPA) by the VA National Acquisition Center for the delivery of the prostate cancer drug Xofigo (radium Ra 223 dichloride) and the pulmonary arterial hypertension medication Adempas (riociguat).
Additionally, Bayer Healthcare Pharmaceuticals Inc. holds an $18.2 million Indefinite Delivery Contract with the Defense Logistics Agency (DLA) Troop Support Medical for supplying pharmaceuticals and medical supplies. Through these contract vehicles, Bayer Healthcare Pharmaceuticals Inc. has provided critical medications such as Xofigo, Adempas, ciprofloxacin antibiotics, praziquantel anthelmintic drugs, and various contraceptive products to support healthcare programs for veterans, active-duty military personnel, and federal medical facilities. All of these contract awards are unrestricted, reflecting Bayer's status as a large, foreign-owned business with the capability to supply specialized pharmaceutical products across multiple therapeutic areas.
Generated 2/25/25, 10:12 AM